-
公开(公告)号：US20250099605A1
公开(公告)日：2025-03-27
申请号：US18805405
申请日：2024-08-14
Inventor： Sabeen Fatima MEKAN , Bilal PIPERDI , Amy Elizabeth OTTO
IPC: A61K47/68 , A61K39/395 , A61P35/00
Abstract: The present disclosure relates to methods of treating a treatment naïve metastatic NSCLC in a patient, comprising administering sacituzumab govitecan (SG) and an anti-PD-1 antibody or antigen binding fragment thereof.
-
公开(公告)号：US20250042961A1
公开(公告)日：2025-02-06
申请号：US18716399
申请日：2022-12-05
Applicant: MERCK SHARP & DOHME LLC , MSD International GMBH , Agency for Science, Technology and Research
Inventor： Hubert Josien , Arun Chandramohan , Charles William Johannes , Christopher J. Brown , Srinivasaraghavan Kannan , Anthony William Partridge , Chandra Shekhar Verma , Lin Yan , Tsz Ying Yuen
IPC: C07K14/47 , A61K31/203 , A61K31/4745 , A61K31/475 , A61K31/495 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K33/243 , A61K38/00 , A61K38/12 , A61K38/14 , A61K39/395
Abstract: Disclosed are p53 peptidomimetic macrocycles, each p53 peptidomimetic macrocycle comprising an i, i+4 olefin staple and a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; an i, i+7 olefin staple and a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; or, an i, i+7 di-alkyne staple and optionally a polypeptide tail covalently linked to the p53 peptidomimetic macrocycle; wherein the p53 peptidomimetic macrocycle comprises all D-configuration amino acids and the polypeptide tail comprises three to nine amino acids, each amino acid of the polypeptide tail independently having a D-configuration or an L-configuration. The p53 peptidomimetic macrocycles are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX, thereby antagonizing MDM2 and MDMX binding to p53. These p53 peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.
-
3.发明公开公开(公告)号：US20240245792A1
公开(公告)日：2024-07-25
申请号：US18525282
申请日：2023-11-30
Applicant: Synthorx, Inc. , MSD INTERNATIONAL GMBH , MSD INTERNATIONAL BUSINESS GMBH
Inventor： Giovanni Abbadessa , Carolina E. Caffaro , Brigitte Demers , Joseph Leveque , Wan-Ju Meng , Marcos Milla , Jerod Ptacin
CPC classification number: A61K47/642 , A61P35/04 , C07K16/22 , C07K16/2818 , C07K16/2863 , A61K2039/507
Abstract: Disclosed herein are methods for treating head and neck squamous cell carcinoma (HNSCC) in a subject in need thereof, comprising administering IL-2 conjugates in combination with one or more additional agents.
-
公开(公告)号：US20240083000A1
公开(公告)日：2024-03-14
申请号：US17943664
申请日：2022-09-13
Applicant: MSD International GMBH
Inventor： Noel Lahart , Brian Mullarkey , John Hayes
CPC classification number: B25B27/02 , F16L33/02 , F16L2201/44
Abstract: A genderless interface connector pull tool is used for removing a membrane from a genderless interface connector. The tool may include a clamp and a hand grip. The clamp is configured to clamp a genderless interface connector and may include a top clamp coupled with a bottom clamp, and a pair of rails located on a top surface of the top clamp. The hand grip may include a grip head which is formed with a hook and one or more openings. The hook is configured to engage with a tab of the genderless interface connector that is connected to a membrane. The one or more openings are dimensioned to fit with the pair of rails so that the hand grip can slide on the rails to pull the tab. Thus, the membrane connected to the tab can be removed from the genderless interface connector along the rails' direction.
-
公开(公告)号：US20240026001A1
公开(公告)日：2024-01-25
申请号：US18201620
申请日：2023-05-24
Applicant: SURFACE ONCOLOGY, INC. , MSD INTERNATIONAL GMBH
Inventor： Alison O'NEILL , Lauren HARSHMAN , Jonathan HILL , Jou-Ku CHUNG , Kerry WHITE , Robert ROSS
CPC classification number: C07K16/2818 , C07K16/244 , A61P35/00 , C07K2317/24 , A61K2039/507
Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody and pembrolizumab.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20230381335A1
公开(公告)日：2023-11-30
申请号：US18447808
申请日：2023-08-10
Applicant: SYNTHORX, INC. , MSD INTERNATIONAL GMBH
Inventor： Giovanni Abbadessa , Carolina E. Caffaro , Brigitte Demers , Joseph Leveque , Wan-Ju Meng , Jerod Ptacin
IPC: A61K47/68 , C07K16/28 , C07K16/24 , A61K31/282 , A61K33/243 , A61P35/00 , A61K31/337 , A61K31/167 , A61K31/138
CPC classification number: A61K47/6845 , C07K16/2818 , C07K16/246 , A61K31/282 , A61K33/243 , A61P35/00 , A61K31/337 , A61K31/167 , A61K31/138
Abstract: Disclosed herein are methods for treating a lung cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with the anti-PD-1 antibody or antigen-binding fragment thereof (e.g., pembrolizumab).
-
公开(公告)号：US20230203175A1
公开(公告)日：2023-06-29
申请号：US17921521
申请日：2021-04-27
Applicant: SEAGEN INC. , MSD INTERNATIONAL GMBH
Inventor： Michael Schmitt , Shyra Gardai
IPC: C07K16/28 , A61K31/337 , A61P35/00
CPC classification number: C07K16/2878 , A61K31/337 , A61P35/00 , C07K16/2896
Abstract: This disclosure relates to methods of treating cancer using a combination of an anti-CD40 antibody such as SEA-CD40, and an anti-PD-1 antibody such as pembrolizumab. The treatment can further include a chemotherapy.
-
公开(公告)号：US20220267376A1
公开(公告)日：2022-08-25
申请号：US17618751
申请日：2020-06-16
Applicant: Tomi K. SAWYER , Pietro ARONICA , Christopher J. BROWN , Fernando J. FERRER , Charles W. JOHANNES , Srinivasaraghavan KANNAN , David P. LANE , Anthony W. PARTRIDGE , Yaw Sing TAN , Chandra S. VERMA , Tsz Ying YUEN , Merck Sharp & Dohme Corp. , Agency for Science, Technology and Research , MSD International GMBH (Singapore Branch)
Inventor： Pietro Aronica , Christopher J. Brown , Fernando J. Ferrer , Charles W. Johannes , Srinivasaraghavan Kannan , David P. Lane , Anthony W. Partridge , Tomi K. Sawyer , Yaw Sing Tan , Chandra S. Verma , Tsz Ying Yuen
Abstract: Peptidomimetic macrocycles that comprise all-D configuration ?-amino acids and bind mouse double minute 2 (MDM2 aka E3 ubiquitin-protein ligase) and MDMX (aka MDM4) are described. These all-D configuration α-amino acid peptidomimetic macrocycles are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX thereby antagonizing MDM2 and MDMX binding to p53. These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.
-
公开(公告)号：US09573959B2
公开(公告)日：2017-02-21
申请号：US14777560
申请日：2014-03-10
Applicant: MSD International GMBH
Inventor： Steven J. Brenek , Stephane Caron , Jade D. Nelson , Mark E. Webster , Rodney Matthew Weekly
IPC: C07D493/08 , C07D317/26 , C07D317/42
CPC classification number: C07D493/08 , C07D317/26 , C07D317/42
Abstract: This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.
Abstract translation: 本发明涉及制备钠葡萄糖转运蛋白2（SGLT2）抑制剂，cocrytalline SGLT2和（S）-5-氧代吡咯烷-2-羧酸（L-PGA）复合物的方法，以及可用于制备所述 SGLT2抑制剂。
-
公开(公告)号：US11883479B2
公开(公告)日：2024-01-30
申请号：US17240224
申请日：2021-04-26
Applicant: GENEXINE, INC. , MSD International GmbH
Inventor： Young Chul Sung , Jung Won Woo , Jong Sup Park , Jin Won Youn
CPC classification number: A61K39/12 , C07K16/2818 , C07K16/2827 , C12N7/00 , A61K2039/507 , A61K2039/53 , C12N2710/20034
Abstract: A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection include administering a combination of a HPV-specific fusion protein and an immunomodulatory agent.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.021 seconds)
